VolitionRx Limited (VNRX)
NYSE American
Price as at 1 Oct 2026, 03:39 UTC. Quotes are delayed.
Fundamentals
Valuation and ratings
VolitionRx Limited trades at $0.26. We do not hold enough of the inputs to value this company with the confidence the estimate implies, so we publish no fair value for it rather than a number we would not defend.
About VolitionRx Limited
VolitionRx Limited, a multi-national epigenetics company, develops blood tests to help detect and monitor a range of cancers, and diseases associated with NETosis in the United States, Europe, and Asia. The company offers Nu.Q Vet, a cancer screening test for dogs and other animals; Nu.Q Nets, detects diseases associated with NETosis, such as sepsis; Nu.Q Discover, a solution to profiling nucleosomes. It also provides Nu.Q Cancer for predicting treatment response, monitoring treatment response and disease progression, and amending a patient's cancer treatment regimen; and Capture-PCR and Capture-Seq, which are isolating and capturing circulating tumor-derived DNA from plasma samples for early cancer detection. VolitionRx Limited is headquartered in Henderson, Nevada.
Company profile, industry and headcount are as reported by our data provider and can lag a company's own filings by a reporting period. The annual report is the authority.
Common questions
Where does SteadyShares get its VNRX data?
Fundamentals for VNRX come from company filings and exchange data, as listed on NYSE American; institutional ownership comes from SEC 13F filings. The share price shown was last refreshed on 1 Oct 2026, 03:39 UTC and is delayed. Metrics we do not hold are left out of the page rather than estimated.
The full research page for VNRX, with financial statements, ownership detail, peer comparison and alerts, is free inside the app.
Data from company filings, exchange quotes and SEC EDGAR 13F disclosures. Quotes are delayed. Metrics we do not have are left out rather than estimated. Educational information, not financial advice.